Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo- controlled study

Journal of Clinical Oncology

Volumn 15, Issue 3, 1997, Pages 955-962

  Delmas, P D ^a   Balena, R ^a   Confravreux, E ^a   Hardouin, C ^a   Hardy, P ^a   Bremond, A ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; OSTEOCALCIN; PLACEBO; RISEDRONIC ACID; TAMOXIFEN;

ABDOMINAL PAIN; ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; FEMALE; FEMUR NECK; FLU LIKE SYNDROME; HUMAN; LIVER TOXICITY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENOPAUSE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031057249     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.3.955     Document Type: Article

References (35)

1. Brzezinski A: Management of menopause in women with breast cancer. J Med Sci 31:163-168, 1995
2. Eden J-A: Estrogen replacement therapy in survivors of breast cancer: A risk benefit assessment. Drugs Aging, 8:127-133, 1996
3. Lindsay R, Hart DM, Forrest C, et al: Prevention of spinal osteoporosis in oophorectomized women. Lancet 2:199-204, 1980
4. Bachmann GA: Nonhormonal alternatives for the management of early menopause in younger women with breast cancer. Monogr Natl Cancer Inst 16:161-171, 1994
5. Colditz G, Hankinson SE, Hunter DJ, et al: The use of estrogens and progestins and the risk of breast cancer in post menopausal women. N Engl J Med 332:1589-1593, 1995
6. Sietsema WK, Ebetino FH, Salvagno AM, et al: Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp Clin Res 15:389-396, 1989
7. Reasner CA, Stone MD, Hosking DJ, et al: Acute changes in calcium homeostasis during the treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 77:1067-1071, 1993
8. Roux C, Ravaud P, Cohen-Solal M, et al: Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 15:41-49, 1994
9. Reginster JY, Zegels B, Valetin-Opran A, et al: Risedronate-related PTH levels in osteoporotic patients and healthy male volunteers, in Christiansen C, Overgard K (eds): Osteoporosis 1990. Proceedings of the Third International Symposium on Osteoporosis, October 14-20, 1990, Copenhagen, Denmark. Copenhagen, Denmark, Osteopress, 1990, pp 1086-1092
10. Bekker, Kylstra J, Altman R, et al: A multicenter study of risedronate for Paget's disease. J Bone Miner Res 9:S292, 1994 (suppl 1, abstr B251)
11. Lowik C, van der Plujm: Mechanisms of action of bisphosphonates: Studies with bone culture systems, in Bijvoet HA, Fleisch H, Canfield RE, et al (eds): Bisphosphonates on Bones. 1995, pp 155-170
12. Saaki A, Boyce BF, Story B, et al: Bisphosphonate risedronate reduces metastic human breast cancer burden in bone in nude mice. Cancer Res 55:3551-3557, 1995
13. Wright CDP, Compston JE: Tamoxifen: Oestrogen or antioestrogen in bone? Q J Med 88:307-310, 1995
14. Powles TJ, Hickidi T, Kanis JA, et al: Effect of tamoxifen on bone mineral density measured by dual energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78-84, 1996
15. Love RR, Mazess RB, Barden MS: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl Med 326:852-856, 1992
16. Uebelhart D, Gineyts E, Chapuy MC, et al: Urinary excretion of pyridinium crosslinks, a new marker of bone resorption metabolic bone disease. J Bone Miner Res 8:87-96, 1990
17. Pouilles JM, Tremollieres F, Bonneu M, et al: Effect of early age at menopause on vertebral bone mass. J. Bone Miner Res 9:311-315, 1994
18. Castelo-Branco C, Pons F, Gonzalez-Merlo J: Bone mineral density in surgically post menopausal women receiving hormonal replacement therapy as assessed by dual photon absorptiometry. Maturitas 16:133-137, 1993
19. Bagur AC, Mautalen CA: Risk for developing osteoporosis in untreated premature menopause. Calcif Tissue Int 51:4-7, 1992
20. Caplan GA, Scane AC, Francis RM: Pathogenesis of vertebral crush fractures in women. J R Soc Med 87:200-202, 1994
21. Singer FR, Minoofar PN: Bisphosphonates in the treatment of disorders of mineral metabolism. Adv Endocrinol Metab 6:259-288, 1995
22. Geddes AD, D'Souza S, Ebetino FH, et al: Bisphosphonates: Structure-activity relationships and therapeutic implications, in Heersche JNM, Kanis JA (eds): Bone Mineral Resources. New York, NY, Elsevier, 1994, pp 265-306
23. McOsker JE, Sietsema WK: Preclinical pharmacology of risedronate, a novel bisphosphonate, in Christiansen C, Overgard K (eds): Osteoporosis 1990. Proceedings of the Third International Symposium on Osteoporosis, October 14-20, 1990, Copenhagen, Denmark. Copenhagen, Denmark, Osteopress, 1990, pp 1079-1081
24. Wronski TJ, Yen C-F, Scott KS: Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats. J Bone Miner Res 6:387-394, 1991
25. Horwitz KB: When tamoxifen turns bad. Endocrinology 136:821-823, 1995
26. Bush-T-L, Heizlsouer-K-J: The role of tamoxifen in breast cancer: Treatment: Yes. Prevention: No. J Women-s Health 4:1059-7115, 1995
27. Parfitt AM: Bone remodeling and bone loss: Understanding the pathophysiology of osteoporosis. Clin Obstet Gynecol 30:789-811, 1987
28. Cumming SR, Nevitt MC, Browner WS, et al: Risk factors for hip fractures in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767-773, 1995
29. Liberman UA, Weiss SR, Broll J, et al: Effect of oral alendronale on bone mineral density and the incidence of fractures in post-menopausal ostoporosis. N Engl J Med 333:1437-1443, 1995
30. Catherine WH, Jordan VC: A risk-benefit assessment of tamoxifen therapy. Drug Safety 8:381-397, 1993
31. Ratcliffe MA, Lanham SA, Reid DM, et al: Bone mineral density (BMD) in patients with lymphoma: The effects of chemotherapy, intermittent corticosteroids and premature menopause. Hematol Oncol 10:181-187, 1992
32. Nguyen Pamart M, Bonneterre J, Hecquet B: Urinary excretion of deoxypyridinoline in patients with breast cancer. Anticancer Res 15:1601-1603, 1995
33. Li F, Pitt PI, Sherwood R, et al: Biochemical markers of bone turnover in women with surgically treated carcinoma of the breast. Eur J Clin Invest 23:566-571, 1993
34. Smith J, Shoukri K, Trahiotis M, et al: Bone marker changes in risedronate-treated post menopausal women. J Bone Miner Res 10:M396, 1995 (abstr)
35. Mortensen L, Bekker P, Van De Ouweland F, et al: Prevention of early post menopausal bone loss by risedronate: A two year study. J Bone Min Res 10:S140, 1995 (suppl 1, abstr)